Navigation Links
WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

is innovative research."

Over the past few years, two genetic variants have been identified that predict an individual's response to warfarin.  Using genetic testing to guide physicians in starting warfarin therapy has the potential to reduce deaths, increase overall patient safety and lower national healthcare system costs.  Given the magnitude of these potential improvements in warfarin use, the Centers for Medicare & Medicaid Services (CMS) has authorized the WARFARIN Study to gather data on the potential impact of a pharmacogenetic test to reduce serious bleeding and clotting episodes in patients.  Upon review of the Study, the first such personalized medicine trial authorized by CMS, the agency may establish reimbursement for the genetic warfarin test, which is marketed by Iverson Genetic Diagnostics.  

Leroy Hood, M.D., Ph.D., co-founder of the Institute for Systems Biology and a member of Iverson Genetic Diagnostics' Board of Directors, commented, "The technological tools for molecular discovery that we continue to develop become truly valuable when they can actually improve human health.  CMS is to be commended for its leadership in authorizing the WARFARIN Study.  This study marks a step towards our goal of improving patient outcomes through personalized care."Researchers have identified two specific genes, VKORC1 (for warfarin sensitivity) and CYP2C9 (for warfarin metabolism), which contribute up to 40% of individual patient variations in response to using warfarin. The WARFARIN Study will assess the extent to which serious adverse events – hemorrhage and clotting – can be avoided when warfarin dosing is guided by genetic testing for these two genes, as compared to warfarin dosing calculated without these pharmacogenetic data.  

"Overlake Hospital Medical Center is one of the key sites in the national WARFARIN Study, which altogether will enroll more than 7,000 patients across the cou
'/>"/>

SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. Pivotal Study Validates Roches cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
3. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
4. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
5. Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. New test to study proteins involved in neurodegenerative diseases
8. A new model for studying Parkinsons
9. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
10. Columbia University researchers use nanoscale transistors to study single-molecule interactions
11. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , NEW YORK, Oct. 26 ... research report is available in its ... Bioinformatics and Computational Biology: Bottlenecks and ... http://www.reportlinker.com/p0156561/Reportlinker-Adds-Bioinformatics-and-Computational-Biology-Bottlenecks-and-Options.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , The interdisciplinary ...
... Germany, October 26 Ziehm Imaging and BrainLAB,have ... intra-operative,guidance of pedicle screw and hardware placement during ... now allows,high-resolution 3D images from the Ziehm Vision2 ... surgical navigation driven by BrainLAB technology. Ziehm,s,Vision2 FD ...
... Pa., Oct. 26 Cadient Group , ... today announced that it has been recognized as one of ... the Greater Philadelphia region for the second consecutive year. ... during the five year period from 2004-2008. Cadient Group ...
Cached Biology Technology:Reportlinker Adds Bioinformatics and Computational Biology: Bottlenecks and Options 2Reportlinker Adds Bioinformatics and Computational Biology: Bottlenecks and Options 3Ziehm Imaging and BrainLAB Improve Trauma and Spine Surgery With X-ray Based Navigation 2Ziehm Imaging and BrainLAB Improve Trauma and Spine Surgery With X-ray Based Navigation 3Ziehm Imaging and BrainLAB Improve Trauma and Spine Surgery With X-ray Based Navigation 4Ziehm Imaging and BrainLAB Improve Trauma and Spine Surgery With X-ray Based Navigation 5Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year 2
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Calif. -- November 9, 2012 -- The Society of Environmental ... to Kevin Brix at the its 33rd Annual Meeting, November ... recently completed his Ph.D. at the Rosenstiel School of Marine ... has already made exceptional contributions to the understanding of fate ...
... November 2012: Scientists at the University of Liverpool ... the English Channel have the potential to affect the ... Channel Islands. The study by the University of ... Trust, funded by the Alderney Commission for Renewable Energy, ...
... International African Vaccinology Conference, Cape Town, South AfricaResults from ... in the New England Journal of Medicine , ... protect African infants against malaria. When compared to immunization ... first vaccination) vaccinated with RTS,S had one-third fewer episodes ...
Cached Biology News:SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2Gannets could be affected by offshore energy developments 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: